For ALK-positive NSCLC, treatment with the tyrosine kinase inhibitor (TKI) crizotinib results in a high objective response rate (ORR) of ∼60%, but the median progression-free survival (mPFS) is only 8-10 months [2], owing to the rapid emergence of acquired drug resistance through a variety of mechanisms [3–6]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.